FindTrial
Sign In

The clinical study of aspirin combined with dydroprogesterone tablets on endometrial hyperplasia in patients

The clinical study of aspirin combined with dydroprogesterone tablets on endometrial hyperplasia in patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057826
Enrollment
Unknown
Registered
2022-03-18
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial hyperplasia

Interventions

Experimental group:Dydroprogesterone + aspirin
Control group:Dydroprogesterone

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. The pathologic examination has confirmed endometrial hyperplasia; 2. Age 20 to 60 years old; 3. Patients during treatment have been informed of the possibility of disease progress, and regular follow-up and may require surgical treatment later, patients agreed to sign a consent form.

Exclusion criteria

Exclusion criteria: 1. Serious diseases of the blood system, kidney dysfunction, autoimmune diseases, or other serious medical problems; 2. Other malignant tumors; 3. Serious mental illness; 4. Poor compliance, patients who can't return on time, or losers.

Design outcomes

Primary

MeasureTime frame
Vaginal ultrasonic scan;Endometrial biopsy;CA125;—

Countries

China

Contacts

Public ContactWen Lv

Tongde Hospital of Zhejiang Province

ww4021@163.com+86 0571-89972338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026